181 related articles for article (PubMed ID: 32631535)
21. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of 2-(phenoxymethyl)-5-phenyl-1,3,4-oxadiazole derivatives as anti-breast cancer agents.
Lakshmithendral K; Saravanan K; Elancheran R; Archana K; Manikandan N; Arjun HA; Ramanathan M; Lokanath NK; Kabilan S
Eur J Med Chem; 2019 Apr; 168():1-10. PubMed ID: 30798049
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.
Zhang XM; Qiu M; Sun J; Zhang YB; Yang YS; Wang XL; Tang JF; Zhu HL
Bioorg Med Chem; 2011 Nov; 19(21):6518-24. PubMed ID: 21962523
[TBL] [Abstract][Full Text] [Related]
24. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
25. Unexpected small molecules as novel SIRT2 suicide inhibitors.
Chen X; Zou Y; Wang J; Cao Z; Liu J; Li Y; Zhao Y; He B
Bioorg Med Chem; 2020 Mar; 28(6):115353. PubMed ID: 32061485
[TBL] [Abstract][Full Text] [Related]
26. Structure activity study of S-trityl-cysteamine dimethylaminopyridine derivatives as SIRT2 inhibitors: Improvement of SIRT2 binding and inhibition.
Radwan MO; Ciftci HI; Ali TFS; Koga R; Tateishi H; Nakata A; Ito A; Yoshida M; Fujita M; Otsuka M
Bioorg Med Chem Lett; 2020 Oct; 30(19):127458. PubMed ID: 32755678
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of [1,2,4]triazolo[4,3-a]quinoxaline-1,3,4-oxadiazole derivatives as potent antiproliferative agents via a hybrid pharmacophore approach.
Kaneko D; Ninomiya M; Yoshikawa R; Ono Y; Sonawane AD; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104293. PubMed ID: 33010622
[TBL] [Abstract][Full Text] [Related]
28. Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities.
Spiegelman NA; Price IR; Jing H; Wang M; Yang M; Cao J; Hong JY; Zhang X; Aramsangtienchai P; Sadhukhan S; Lin H
ChemMedChem; 2018 Sep; 13(18):1890-1894. PubMed ID: 30058233
[TBL] [Abstract][Full Text] [Related]
29. New indenopyrazole linked oxadiazole conjugates as anti-pancreatic cancer agents: Design, synthesis, in silico studies including 3D-QSAR analysis.
Khan I; Ganapathi T; Rehman MM; Shareef MA; Kumar CG; Kamal A
Bioorg Med Chem Lett; 2021 Jul; 44():128094. PubMed ID: 33964437
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Oh CH
Eur J Med Chem; 2015 Jan; 90():45-52. PubMed ID: 25461310
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and anticancer activities evaluation of novel 5H-dibenzo[b,e]azepine-6,11-dione derivatives containing 1,3,4-oxadiazole units.
He X; Li XY; Liang JW; Cao C; Li S; Zhang TJ; Meng FH
Bioorg Med Chem Lett; 2018 Mar; 28(5):847-852. PubMed ID: 29456106
[TBL] [Abstract][Full Text] [Related]
32. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
Valente S; Trisciuoglio D; De Luca T; Nebbioso A; Labella D; Lenoci A; Bigogno C; Dondio G; Miceli M; Brosch G; Del Bufalo D; Altucci L; Mai A
J Med Chem; 2014 Jul; 57(14):6259-65. PubMed ID: 24972008
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro antiproliferative activities of (5-aryl-1,2,4-oxadiazole-3-yl) methyl d-ribofuranosides.
Avanzo RE; Padrón JM; D'Accorso NB; Fascio ML
Bioorg Med Chem Lett; 2017 Aug; 27(16):3674-3677. PubMed ID: 28716494
[TBL] [Abstract][Full Text] [Related]
34. Design and evaluation of novel oxadiazole derivatives as potential prostate cancer agents.
Mochona B; Qi X; Euynni S; Sikazwi D; Mateeva N; Soliman KF
Bioorg Med Chem Lett; 2016 Jun; 26(12):2847-2851. PubMed ID: 27156770
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of 3,4-diaryl-1,2,5-oxadiazole-2/5-oxides as highly potent inhibitors of tubulin polymerization.
Hong Y; Zhao Y; Yang L; Gao M; Li L; Man S; Wang Z; Guan Q; Bao K; Zuo D; Wu Y; Zhang W
Eur J Med Chem; 2019 Sep; 178():287-296. PubMed ID: 31195170
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antiproliferative assay of 1,3,4-oxadiazole and 1,2,4-triazole derivatives in cancer cells.
Tu G; Yan Y; Chen X; Lv Q; Wang J; Li S
Drug Discov Ther; 2013 Apr; 7(2):58-65. PubMed ID: 23715503
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of imidazopyridinyl-1,3,4-oxadiazole conjugates as apoptosis inducers and topoisomerase IIα inhibitors.
Subba Rao AV; Vishnu Vardhan MV; Subba Reddy NV; Srinivasa Reddy T; Shaik SP; Bagul C; Kamal A
Bioorg Chem; 2016 Dec; 69():7-19. PubMed ID: 27656775
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Chen S; Guo W; Liu X; Sun P; Wang Y; Ding C; Meng L; Zhang A
Eur J Med Chem; 2019 Oct; 179():38-55. PubMed ID: 31233921
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, in silico and biological evaluation of new indole based oxadiazole derivatives targeting estrogen receptor alpha.
Kaur K; Verma H; Gangwar P; Jangid K; Dhiman M; Kumar V; Jaitak V
Bioorg Chem; 2024 Jun; 147():107341. PubMed ID: 38593531
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.
Loboda KB; Valjavec K; Štampar M; Wolber G; Žegura B; Filipič M; Dolenc MS; Perdih A
Bioorg Chem; 2020 Jun; 99():103828. PubMed ID: 32315896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
